文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛儿科与产科急症

儿童心脏病患者ECPR后严重功能损害或死亡的预测建模:为干预性试验做准备

Modeling severe functional impairment or death following ECPR in pediatric cardiac patients: Planning for an interventional trial.
PubMed 文献 · Resuscitation · 2021-08-10
一句话结论儿童ECPR后院内死亡率52%,可用入院FSS、单心室生理、ECMO时长、平均PELOD-2及最差mASPECTS构建高精度模型预测出院时严重功能损害或死亡。

该单中心回顾性研究纳入2011–2019年182例因院内心脏骤停合并先天性心脏病接受ECPR的患儿(中位年龄148天),主要终点为出院时严重功能损害或死亡(FSS≥16)。院内死亡率为52%,87%死于撤除生命支持,其中50%撤除决策中严重神经损伤为促进因素;出院存活者中位FSS为8,仅1例严重功能损害。6个月死亡率为57%。多变量模型显示入院FSS、单心室生理、ECMO时长、平均PELOD-2及最差mASPECTS为独立预测因子,出院时AUC=0.931,6个月AUC=0.924。

要点

  • 儿童ECPR后院内死亡率52%,6个月死亡率57%,出院存活者中位FSS为8(IQR 6–8),仅1例存活者存在严重功能损害。
  • 110例接受神经影像的患儿中47%存在缺氧缺血性损伤、41%存在出血,提示ECPR后神经影像异常高发。
  • 撤除生命支持占死亡的87%,其中严重神经损伤在50%的撤除决策中为促进因素。
  • 预测FSS≥16的独立因子包括入院FSS、单心室生理、ECMO时长、平均PELOD-2及最差mASPECTS(或DWI-ASPECTS),模型AUC=0.931。
  • 利用ECPR后28天内的每日数据可高精度建模出院时严重功能损害或死亡,可能为未来干预性试验提供终点。

适用人群与场景

  • 2011–2019年单中心所有ECPR事件中,因院内心脏骤停合并先天性心脏病接受ECPR的儿童患者(182例,中位年龄148天,IQR 14–827)。

诊断标准与关键阈值

  • 主要终点为出院时严重功能损害或死亡,定义为功能状态评分(FSS)≥16。
  • 器官功能障碍采用儿科逻辑器官功能障碍评分-2(PELOD-2)分级;神经影像采用改良Alberta卒中项目早期CT评分(mASPECTS)评估。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • ECPR后神经影像显示缺氧缺血性损伤(110例中52例,47%)或出血(45例,41%),需警惕严重神经损伤。
  • 撤除生命支持占院内死亡的87%,其中严重神经损伤在50%的撤除决策中为促进因素。

研究设计与关键结果

  • 单中心回顾性研究,纳入182例院内心脏骤停合并先天性心脏病并接受ECPR的患儿(中位年龄148天,IQR 14–827)。
  • 院内死亡率为52%;出院存活者中位FSS为8(IQR 6–8),仅1例存活者存在严重功能损害。
  • 6个月死亡率为57%,存活者中位FSS为6(IQR 6–8,n=79)。
  • 多变量模型确定入院FSS、单心室生理、ECMO时长、平均PELOD-2及最差mASPECTS(或DWI-ASPECTS)为FSS≥16的独立预测因子,出院时AUC=0.931,6个月AUC=0.924。

证据类型、等级与局限

  • 证据类型:单中心回顾性队列研究。
  • 局限:单中心、回顾性设计,样本量182例,预测模型需前瞻性验证。

对床旁实践的改变

  • 儿童ECPR后可用入院FSS、单心室生理、ECMO时长、平均PELOD-2及最差mASPECTS等每日数据建模预测出院时严重功能损害或死亡,辅助预后沟通与撤除生命支持决策。
  • 该模型为 prognostically valuable tool,可能识别未来干预性试验的终点,但原文未提及具体决策阈值,需前瞻性验证后用于临床决策。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

AIM: We aimed to characterize extracorporeal CPR (ECPR) outcomes in our center and to model prediction of severe functional impairment or death at discharge.

METHODS: All ECPR events between 2011 and 2019 were reviewed. The primary outcome measure was severe functional impairment or death at discharge (Functional Status Score [FSS] ≥ 16). Organ dysfunction was graded using the Pediatric Logistic Organ Dysfunction Score-2, neuroimaging using the modified Alberta Stroke Program Early Computed Tomography Score. Multivariable logistic regression was used to model FSS ≥ 16 at discharge.

RESULTS: Of the 214 patients who underwent ECPR, 182 (median age 148 days, IQR 14-827) had an in-hospital cardiac arrest and congenital heart disease and were included in the analysis. Of the 110 patients who underwent neuroimaging, 52 (47%) had hypoxic-ischemic injury and 45 (41%) had hemorrhage. In-hospital mortality was 52% at discharge. Of these, 87% died from the withdrawal of life-sustaining therapies; severe neurologic injury was a contributing factor in the decision to withdraw life-sustaining therapies in 50%. The median FSS among survivors was 8 (IQR 6-8), and only one survivor had severe functional impairment. At 6 months, mortality was 57%, and the median FSS among survivors was 6 (IQR 6-8, n = 79). Predictive models identified FSS at admission, single ventricle physiology, extracorporeal membrane oxygenation (ECMO) duration, mean PELOD-2, and worst mASPECTS (or DWI-ASPECTS) as independent predictors of FSS ≥ 16 (AUC = 0.931) and at 6 months (AUC = 0.924).

CONCLUSION: Mortality and functional impairment following ECPR in children remain high. It is possible to model severe functional impairment or death at discharge with high accuracy using daily post-ECPR data up to 28 days. This represents a prognostically valuable tool and may identify endpoints for future interventional trials.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Sperotto F, Saengsin K, Danehy A, et al. Modeling severe functional impairment or death following ECPR in pediatric cardiac patients: Planning for an interventional trial. Resuscitation. 2021. PMID: 34389452. doi:10.1016/j.resuscitation.2021.07.041

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。